Company ProfilePremium

ChunLab, Inc.

Company Profile Analysis

Ticker: 311690.KQ주식회사 씨제이바이오사이언스

ESOMAR 23 Corporate BadgeISO Certifications Badge
ChunLab, Inc. - Company showcase

Year Founded & Workforce

2009

83 Employees

ChunLab, Inc. logo

ChunLab, Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

ChunLab, Inc. Overview

MetricFY2023FY2024FY2025H1-2026
Employees (headcount, period-end)——12483

Note: the FY2025 column holds the end-June 2025 figure (124), as reported in a CJ affiliate headcount comparison.

CJ Bioscience is the red-biotechnology (pharmaceutical and healthcare) arm of CJ CheilJedang. It was built on ChunLab, a Seoul National University spin-out that pioneered microbial genomics and bioinformatics. Its core intellectual capital is a precision microbial taxonomy platform (EzBioCloud, now the AI-augmented Ez-Mx platform), large Korean human-microbiome datasets, a strain library, and the discovery platforms (MicroRx, MicroDx) and candidates acquired from the UK's 4D pharma in 2023.

From 2022 to 2025 the company positioned itself as a microbiome-therapeutics developer. Its lead asset, CJRB-101, an oral live biotherapeutic tested with pembrolizumab, was voluntarily terminated after Phase 1 in May 2026. Management has since rebalanced toward "Health & Wellness": personalised gut-microbiome testing and precision-nutrition solutions linked to CJ's health-functional-food business, alongside earlier-stage drug programmes (CJRB-201, CJRB-302, CJRB-401). Revenue is under KRW 4 bn a year against R&D spending above KRW 20 bn. The company depends on parent funding and faces tightening KOSDAQ listing-maintenance thresholds.


What the company does

CJ Bioscience works in two connected areas.

Microbial bioinformatics platform and solutions. This is the original ChunLab business. ChunLab built a genome-based, high-resolution microbial reference database and cloud analysis environment, EzBioCloud. It offered next-generation sequencing (NGS) analysis services, bioinformatics software (CLcommunity, CLgenomics), and a "NGS/BI total solution" for academic, government and industrial customers.

At the time of the IPO (2019), the company described its microbiome reference database as cited more than 8,500 times in the global literature. It also reported:

  • more than 120,000 human-microbiome data sets;

  • more than 5,924 novel taxa identified through its Precision Taxonomy Platform (as of August 2019).

In 2019 it launched the beta version of TrueBac ID, described as the first genome-based solution for bacterial identification in infection diagnostics. At that time it was pursuing FDA clearance for TrueBac ID as Software as a Medical Device (SaMD).

Microbiome-based healthcare and therapeutics. This includes:

  • consumer and clinical gut-microbiome monitoring (Smilebiome; the Pibio app-linked personalised probiotic service launched around 2020; and the "Smile Gut" (스마일 것) gut-microbiome test referenced by management in 2025);

  • since 2022, a drug-discovery pipeline of live biotherapeutic products (LBPs).

After the CJ acquisition, CJ CheilJedang folded its existing red-bio assets (strain library, fermentation know-how, therapeutics research) into the company in January 2022.

Revenue model

Revenue type (latest disclosed mix, Q2-2026)Share of revenue (%)
Microbial bioinformatics platform & solutions (services/subscriptions/analysis)86
Microbiome-based healthcare (testing/consumer solutions)14
Licensing / milestone income0
Therapeutic product sales0

Revenue is almost entirely service and solution revenue:

  • microbial genome analysis and bioinformatics solutions;

  • microbiome-based personalised healthcare services.

Industry press summarising DART filings consistently describes revenue this way. A market-data summary of the Q2-2026 disclosure gives the revenue split as:

  • "microbial bioinformatics platform and solutions": 86%;

  • "microbiome-based healthcare": 14%.

No product-sale revenue from approved therapeutics exists. No licensing (technology-transfer) revenue has been recognised: the 2024 target of three technology-out deals by 2026 had not been met as of October 2026.

Source: Butler.works summary of company disclosures (Q2-2026 revenue basis).

Value chain position

The company sits upstream in the microbiome value chain, covering:

  • reference data, strain identification and taxonomy;

  • multi-omics analytics and biomarker discovery (Ez-Mx);

  • candidate discovery (Ez-Mx combined with 4D pharma's MicroRx);

  • early clinical development.

It does not own GMP manufacturing for live biotherapeutics. At the IPO stage it had arranged CMO/CDMO cooperation with GC Green Cross (2019 MOU). In the wellness channel, it supplies science (testing, strain evidence, precision-nutrition algorithms). Consumer product commercialisation sits with group affiliates, notably CJ Wellcare, CJ CheilJedang's health-functional-food subsidiary formed in 2022.

Customer types and end-markets

Customer typeOfferingEnd-market
Academic and government research institutesEzBioCloud, NGS/BI analysis, national R&D projectsLife-science research tools & services
Public-sector tendersMicrobial genome analysisGovernment bioinformatics procurement (affected after CJ affiliation; see 2.5)
Hospitals and clinicsGut-microbiome analysis services (e.g., Mediram Korean Medicine Hospital, Sun Medical Center, BeautyOn Clinic)Clinical/precision health
Consumers (direct or via partners)Smilebiome, Smile Gut testing, personalised nutrition (MAC solution planned H2-2026)Consumer wellness / precision nutrition
Pharma / biotech (target)Licensing of LBP candidates and platformMicrobiome therapeutics
Group affiliates (CJ CheilJedang, CJ Wellcare)Strain/microbiome science for health-functional foodsProbiotics / functional foods

Company's own characterisation versus independent characterisation

Company's description. Recent company language (2024 vision; 2025–2026 disclosures and press releases) has evolved:

  • At launch (Jan 2022): "Global No.1 microbiome company".

  • 2024 vision: "A global innovator in healthcare through AI-powered microbiome science", with the mission "Contributing to global health with ONLYONE therapeutics and solutions".

  • After the May 2026 termination of CJRB-101: the company says it will pursue drug development and a premium wellness business in parallel. It aims to strengthen a profitability- and cash-flow-centred structure based on validated strain assets and clinical data, building a microbiome-based "Health & Wellness" business. (Paraphrased from the company statement accompanying the 12 May 2026 disclosure.)

Independent characterisation. CJ Bioscience is best described as a subscale microbiome bioinformatics service company carrying a parent-funded R&D programme whose most advanced clinical asset has now been discontinued. The facts behind this view:

Revenue fell after the acquisition: Revenue declined from about KRW 5.3 bn (2020, pre-acquisition) to KRW 3.5–3.7 bn (2024–2025). Management attributed part of this to losing preferential access to public tenders once the company became a large-business-group affiliate rather than an SME.

Revenue is far below spending: R&D expense of KRW 19–23 bn a year has run at roughly 4–7 times revenue.

The strategic logic now rests on wellness: The company is converting its microbiome science into consumer and clinical wellness revenue inside the CJ ecosystem. That is lower-risk but also lower-value than the original licensing thesis.

Strategy

Evolution of stated strategy

PeriodStated vision / themesQuantitative targetsOutcome
IPO (2019)Global expansion of bioinformatics platform; microbiome diagnostics and therapeutics; "test–diagnose–treat–manage" total healthcareNot quantifiedPlatform revenue stagnated
Launch (Jan 2022)"Global No.1 microbiome company." Three innovation-growth strategies: (1) ultra-gap R&D (cohorts, global microbiome big data, bio-digital platform); (2) bio-digital-platform-based drug development; (3) global expansion of new businesses (NGS, genomic diagnostics, CDMO, personalised health-functional food)10 pipelines and 2 technology-outs by 2025; US FDA Phase 1 entry within 2–3 years15 pipelines reached (2023); FDA Phase 1 achieved (2023); 0 technology-outs
New Vision (Jun 2024)"A global innovator in healthcare through AI-powered microbiome science"; AX (digital-to-AI transformation); synergy with CJ CheilJedang foods and health-functional foods3 technology-outs by 2026 (CJRB-101, CJRB-201, CJRB-302)Lead asset CJRB-101 terminated May 2026; target widely assessed as unachievable
Post-termination (May 2026 onward)Parallel pursuit of drug development and premium wellness; profitability- and cash-flow-centred structure; "Health & Wellness" based on validated strains and clinical dataMAC personalised solution launch in H2-2026In progress

Strategic initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDescriptionStatus
Parent-funded recapitalisationDec 2024KRW 40 bn placement to CJ CheilJedang to fund CJRB-101 and follow-on pipeline and the AI microbiome platform businessCompleted
Leadership transitionJul–Aug 2025Commercially oriented pharma executive (Yoon) replaces scientist-founderCompleted
Clinical-network wellness rolloutJan–Mar 2026Gut-microbiome analysis at Mediram Korean Medicine Hospital; MOU with Sun Medical Center; skin–gut joint research MOU with BeautyOn ClinicOngoing
Korean microbiome reference assetsJan–Feb 2026Life-cycle gut-microbiome map; scientific evidence for personalised dietary solutionsPublished
Pipeline rebalancingMay 2026CJRB-101 terminated; clinical data and know-how to be applied to follow-on programmesCompleted
Precision-nutrition platformJun 2026Ez-Mx + DIGEST/DIGEST-Flow + 186-person human study + ML prediction; target applications include gut health, GLP-1 side-effect mitigation and metabolic diseaseDisclosed
MAC personalised solutionH2-2026 (planned)Product commercialisation from MAC human-application studyLaunch not confirmed in sources as of 19 Oct 2026
Cost reduction2025–2026Headcount down ~33% YoY to 83; H1-2026 operating loss down 13%Ongoing; no formal cost target disclosed

Parent context. On 1 July 2026, CJ CheilJedang reorganised into three divisions: Lifestyle Food, Technology Materials and Core Materials. Coverage in 2024–2026 links CJ CheilJedang's portfolio review (including a reported exploration of a green-bio sale in Nov 2024) to CJ Bioscience's funding outlook.

ESG commitments. None specific to CJ Bioscience were identified.

Medium-term guidance

No numerical revenue or profit guidance has been published. The only quantified medium-term goal, three technology-outs by 2026, has effectively lapsed.

The binding external constraints are the KOSDAQ listing-maintenance thresholds:

Pre-tax loss test: pre-tax continuing loss exceeding 50% of equity in two of the last three years.

Revenue floor: currently KRW 3 bn.

Tightening revenue floor: the Financial Services Commission plans to raise it to KRW 5 bn in 2027 and KRW 10 bn in 2029 (as reported by IB Tomato, Apr 2025).

Products & Services

Microbial bioinformatics platform & solutions

Product / platformDescription and capabilitiesTarget customerLaunch / latestPricing model
EzBioCloudGenome-based microbial reference database and cloud bioinformatics service for taxonomic identification and microbiome profiling. ChunLab's flagship; its reference database had 8,500+ literature citations by 2019.Academic, government and industry microbiology labs worldwidePre-2019; ongoingNot disclosed (historically web/cloud service; analysis-based fees)
Precision Taxonomy PlatformProprietary high-resolution taxonomic classification combining BT/IT. By Aug 2019 it had identified 5,924+ novel taxa. Underpins diagnostics and candidate discovery.Internal; partners2019 disclosure—
Ez-Mx platform (이지엠)AI-augmented microbiome biomarker and precision-analysis platform. Species-level resolution claimed to exceed public databases. Used for drug-candidate discovery and Korean gut-microbiome typing.Internal R&D; wellness partnersReferenced 2023; enhanced under 2024 AI vision—
NGS/BI total solutionEnd-to-end sequencing plus bioinformatics analysis serviceResearch institutes, public projectsPre-2019Project-based
CLcommunityMicrobiome data analysis software (listed as main product in Korean registries)ResearchersPre-2019Licence (not disclosed)
CLgenomicsMicrobial genome analysis softwareResearchersPromoted 2014Licence (not disclosed)
TrueBac IDWhole-genome-based bacterial identification for infection diagnosis. Beta launched Sep 2019; FDA SaMD pathway pursued at IPO.Clinical microbiology labsBeta 2019—
COVID-19 variant analysis platformRapid (claimed ~10-minute) transmission-path and variant analysis of SARS-CoV-2 genomes (ChunLab-era press)Public health / researchers~2020–2021—
MicroDx (acquired from 4D pharma)Microbiome-profiling-based diagnostics platformInternalAcquired Mar 2023—

Microbiome-based healthcare and wellness

Product / serviceDescriptionTarget customerLaunch / latestPricing model
Smilebiome (스마일바이오미)Human-microbiome monitoring serviceConsumers / clinicsPre-2019Test-based (not disclosed)
Personalised microbiome healthcare service with Pibio appThree-step model: diagnose microbiome (questionnaire or lab analysis), prescribe customised probiotics, track changes via app. The company said three common microbiome types exist in Korea.Consumers~2020—
Smile Gut (스마일 것) gut-microbiome testGut-microbiome testing service cited by management (2025) as a new revenue sourceConsumers, clinicsReferenced 2025—
Clinical gut-microbiome analysis serviceDeployed with partner institutions: Mediram Korean Medicine Hospital (Jan 2026); Sun Medical Center MOU (Jan 2026); BeautyOn Clinic Dolgoji skin–gut research MOU (Mar 2026)Hospitals/clinics2,026B2B (not disclosed)
Korean life-cycle gut-microbiome mapReference atlas of Korean gut microbiome across life stages, supporting personalised productsInternal / partnersAnnounced 19 Jan 2026—
Microbiome-friendly diet scoreModel predicting gut-microbiome/diet correlations; based on 543 Korean subjects' dataWellness product designIHMC Jun 2026—
DIGEST / DIGEST-Flow (patent pending)In-vitro gut-simulation platform reproducing digestion and gut microbial ecology to test foods or functional ingredients. In a 186-person dietary intervention trial, the in-vitro predicted microbial shifts were mirrored in humans (company claim).Internal; food/supplement partnersDisclosed Jun 2026—
ML response-prediction modelPredicts individual responses to foods or nutrition solutions; ROC-AUC 0.85 reportedInternalJun 2026—
Personalised "MAC" solutionPrecision-nutrition product based on MAC human-application study; planned commercial launch in H2-2026. Launch not yet confirmed as of 19 Oct 2026 in sources reviewed.ConsumersPlanned H2-2026—

Therapeutics pipeline (live biotherapeutic products)

ProgrammeModality / originIndicationStatus (Oct 2026)Notes
CJRB-101Oral LBP. Strain derived from fermented-food Leuconostoc mesenteroides, from CJ's strain library and listed on EFSA's safety list. Reported mechanism: TLR4 agonism / immune activation.Advanced or metastatic NSCLC, HNSCC, melanoma (with pembrolizumab), including checkpoint-inhibitor-refractory patientsTerminated after Phase 1 (disclosed 12 May 2026). Phase 2 not pursued.Phase 1 planned up to 46 patients; Phase 2 up to 120. Sites: Severance, Samsung Medical Center, UC Irvine, Univ. of Pittsburgh. Lead investigator Prof. Cho Byoung Chul (Yonsei).
CJRB-201LBP (in-house)Inflammatory bowel disease (IBD)PreclinicalJun 2026 preclinical data: mucus-barrier maintenance, epithelial recovery, energy-metabolism gene expression; weight-loss, inflammation and tissue-damage improvements in animals
CJRB-302LBP (likely 4D-derived; origin not confirmed)Parkinson's disease / degenerative brain diseasePreclinical / earlyNamed as a 2024 technology-out target
CJRB-401LBPAsthmaEarly stageListed as active by company in May 2026
4D pharma-derived assets (9 candidates acquired)Single-strain LBPs from MicroRxSolid tumours, IBD, IBS, asthma, Parkinson'sStatus by asset not disclosedPre-acquisition 4D assets included MRx0518 (immuno-oncology) and MRx0005/MRx0029 (Parkinson's; FDA IND cleared under 4D). Whether CJ is advancing these specific codes is not disclosed.
CLCC1ChunLab-era candidate from Precision Taxonomy Discovery PlatformHepatocellular carcinoma (monotherapy); colorectal cancer (co-administration)Animal efficacy shown (2020); current status not disclosedNot listed in post-2023 pipeline summaries reviewed
Legacy programmesMicrobiome combinationsCombination oncology, NASH, autism spectrum disorderResearch-stage at IPO (2019); current status not disclosed—

Pipeline count history:

  • 15 programmes in July 2023 (4 in-house plus 11 from 4D);

  • 15 programmes in June 2024, of which 7 had moved beyond the earliest discovery stage per company commentary.

A post-termination pipeline count was not disclosed.

Financial Narrative

Sources: DART annual reports as summarised by Dealsite (FY2022 preliminary disclosure, 14 Feb 2023), Medigate News, Dailypharm, CEO Score Daily, Dealsite (FY2025), Butler.works and ChickStock. Consolidated K-IFRS; fiscal years ending 31 December.

Income statement

Notes:

  • FY2021 growth uses FY2020 revenue of KRW 5.3 bn.

  • FY2023 and FY2024 growth rates are derived; FY2022 and FY2025 rates are as reported.

  • TTM EPS to H1-2026 is reported by a data vendor at KRW -1,707.

  • No dividends have been paid since listing (accumulated deficit; loss-making).

Margins (derived, %)

Revenue CAGR FY2021–FY2025 (derived): about -4.2% per year (KRW 4.4 bn to KRW 3.7 bn). Over FY2020–FY2025 (KRW 5.3 bn to KRW 3.7 bn), the CAGR is about -6.9% per year.

Interim results 2025–2026

Notes:

  • Q1-2025 revenue is derived from the reported 14.2% YoY decline to KRW 0.783 bn in Q1-2026.

  • Q2-2026 figures are derived as H1 less Q1 (vendor calculation).

  • H1-2026 operating loss narrowed 13% YoY, consistent with the headcount reduction (124 to 83) and the wind-down of CJRB-101.

Earlier interim reference points:

  • Q1-2024 operating loss: KRW 7.8 bn.

  • 9M-2023: revenue KRW 4.1 bn (+59% YoY) and operating loss KRW 25.0 bn (versus KRW 20.7 bn).

Balance sheet

Additional disclosed or derived data points:

Cash: cash plus short-term financial instruments fell to KRW 38.7 bn at end-Q3 2023, before the Q3-2023 rights proceeds settled and the Dec 2023 building sale (KRW 33.1 bn).

Equity at H1-2026 (derived): BPS of KRW 3,195 times about 13.3 m shares outstanding gives roughly KRW 42.5 bn. Shares outstanding are derived from KRW 49.5 bn market cap divided by the KRW 3,720 share price.

Shares outstanding reconciliation (derived): about 5.85 m shares post-Oct-2021, plus 3.23 m (2023 rights), plus 3.95 m (Dec-2024 placement), gives about 13.0 m shares. This is consistent with market-data share counts.

Liquidity: a market-data vendor describes liquidity as adequate but interest coverage as absent.

Cash flow: notes and sources

Note: buybacks are shown as 0 because no buyback programme was identified.

R&D expense

Pre-acquisition R&D ran at "around KRW 5 bn" a year (Dailypharm). FY2023 % of revenue is derived. H1-2025 R&D was KRW 9.2 bn (543% of revenue). Q1-2026 R&D was KRW 3.3 bn, more than four times revenue.

Ratios

Notes:

  • ROE is taken from a market-data vendor using latest reported equity. TTM ROE to H1-2026 is -53.4%.

  • EBITDA is negative, so net debt/EBITDA and interest coverage are not meaningful.

Commentary on trends, inflections and drivers

Revenue. Revenue has not recovered to its pre-acquisition level (KRW 5.3 bn in FY2020). Management gave two explanations for the FY2022 decline:

Loss of SME status: As an SME, ChunLab could win pharma-biotech public tenders on a preferential basis. As a CJ affiliate (large business group), it became largely ineligible.

Management focus: Resources were redirected toward drug discovery.

FY2023's rebound to KRW 5.6 bn did not persist: FY2024 fell to KRW 3.5 bn, close to the KOSDAQ KRW 3 bn revenue threshold. FY2025 recovered modestly to KRW 3.7 bn. H1-2026 was flat at KRW 1.68 bn. Q1-2026 fell 14.2% YoY; Q2-2026 rose 14.5%.

Operating losses. Losses tripled after the acquisition, from KRW 10.1 bn in FY2021 to KRW 32–34 bn in FY2022–FY2024. The drivers were:

  • non-clinical studies;

  • FDA IND preparation;

  • academic collaborations (e.g., Harvard);

  • specialist hiring;

  • from late 2023, two-country clinical operations for CJRB-101.

FY2025 marked the first meaningful contraction, to KRW 24.8 bn (27.5% narrower). This coincided with Phase 1 enrolment completing in March 2025 and the leadership change in August 2025. H1-2026 losses narrowed further, to KRW 11.7 bn.

Net income versus operating income.

  • FY2021 net loss (KRW 19.3 bn) exceeded the operating loss (KRW 10.1 bn), implying sizeable non-operating charges around the change of control.

  • FY2023 net loss (KRW 22.9 bn) was smaller than the operating loss (KRW 32.1 bn), consistent with a non-operating gain, plausibly the December 2023 building sale. That gain is not confirmed in sources reviewed.

Funding pattern. The company has relied on:

  • the 2021 CJ subscription (KRW 73.2 bn);

  • the 2023 rights offering (KRW 45.6 bn);

  • the 2023 building sale to the parent (KRW 33.1 bn);

  • the 2024 parent placement (KRW 40.0 bn);

  • in 2025, rising short-term borrowings.

The accumulated deficit reached KRW 143.3 bn by end-2025. Asia Today (May 2026) reported that CJ CheilJedang has committed about KRW 160 bn to the company in total since 2021.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment (Revenue Share, %) Overview

Segment (revenue share, %)Q2-2026

Microbial bioinformatics platform & solutions (% of revenue)

86

Microbiome-based healthcare (% of revenue)

14

Revenue by Segment

Segment (revenue, KRW Bn)FY2023FY2024FY2025

Total company revenue (KRW Bn)

5.63.53.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

4.44.075.63.53.7

Revenue growth YoY (%)

-17.0-6.637.6-37.56.5

Operating income (KRW Bn)

-10.1-33.2-32.1-34.2-24.8

Net income (KRW Bn)

-19.3-34.9-22.9-32.8-24.0

Dividends per share (KRW)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Operating margin (%)

-230-816-573-977-670

Net margin (%)

-439-857-409-937-649

Income Statement

MetricQ1-2025H1-2025Q1-2026Q2-2026H1-2026

Revenue (KRW Bn)

0.911.680.780.901.68

Operating income (KRW Bn)

—-13.55-5.3-6.4-11.74

Net income (KRW Bn)

———-6.2—

R&D expense (KRW Bn)

—9.23.3——

Key Financials

MetricFY2021FY2022FY2025

Cash & equivalents + short-term financial instruments (KRW Bn)

80.049.3—

Retained earnings / accumulated deficit (KRW Bn)

——-143.3

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (KRW Bn)

————-23.4

Dividends paid (KRW Bn)

00000

Share buybacks (KRW Bn)

00000

Equity raised (KRW Bn)

73.2045.640.00

Asset disposals – HQ building (KRW Bn)

0033.100

Key Financials and Margin Analysis (%)

MetricFY2022FY2023FY2024

R&D expense (KRW Bn)

18.922.523.0

R&D as % of revenue (%)

464402663

Returns & Leverage Ratios (%)

RatioFY2025

ROE (%)

-53.5

Revenue by Region

Region (revenue, KRW Bn)FY2023FY2024FY2025

Total (KRW Bn)

5.63.53.7

Share Price & Returns

ReferenceDatePrice (KRW)

IPO price

Dec 2019

40,000

CJ secondary purchase price

Jul 2021

40,000

CJ new-share subscription price

Jul 2021

37,465

Close before rights announcement

22 May 2023

30,650

Rights offering final price

Aug 2023

14,110

Pre-rumour close

18 Nov 2024

8,750

Limit-up close (bio sale rumour)

20 Nov 2024

14,780

Third-party allotment price

Dec 2024

10,119

52-week high

22 Dec 2025

10,200

Post-IHMC trading

5 Jun 2026

3,655–3,980

52-week low

30 Jul 2026

3,060

Latest close

19 Oct 2026

3,720

Capital Markets

Metric5-yearSince IPO

Share price change (%)

-90.7-90.7

Market Valuation

MetricFY2020FY2023FY2026

Market capitalisation (KRW Bn)

185.2180.249.5

Valuation Multiples

MultipleCJ BioscienceIndustry median (vendor peer set)

P/E

-2.22x (n.m.)

—

P/B

1.19x

1.26x (34 companies)

P/S

13.38x

3.01x (34 companies)

EV/EBITDA

n.m. (negative EBITDA)

—

Share Count (millions) and Returns & Leverage Ratios

MetricFY2021FY2022FY2023FY2024FY2025

New shares issued (millions)

1.9503.233.950

Gross equity proceeds (KRW Bn)

73.2045.640.00

Analyst Conclusions

Management guidance

No numerical guidance. Management's stated priorities after May 2026 are:

  1. parallel drug development (CJRB-201 IBD, CJRB-302 Parkinson's, CJRB-401 asthma, 4D-derived assets);

  2. a premium wellness business built on validated strains and clinical data;

  3. a profitability- and cash-flow-centred structure;

  4. product launch of the personalised MAC precision-nutrition solution in H2-2026.

Consensus growth expectations

None available (no sell-side coverage identified).

Bull case

  1. Wellness monetisation via CJ channels. The precision-nutrition stack (Ez-Mx, DIGEST, 186-person validation, ROC-AUC 0.85 prediction model) plus CJ Wellcare's established probiotic brand and online export channels could lift revenue above the KRW 5 bn (2027) threshold with modest unit volumes. Revenue is so small (KRW 3.7 bn) that even a KRW 2–3 bn wellness contribution would be a large percentage gain.

  2. Cost reset drives loss narrowing. Operating losses have already fallen from KRW 34.2 bn (FY2024) to KRW 24.8 bn (FY2025) and to KRW 11.7 bn in H1-2026. With CJRB-101 clinical costs gone and headcount at 83, a run-rate loss near or below KRW 20 bn reduces funding needs and dilution.

  3. Option value in preclinical assets and platforms. CJRB-201 (IBD) preclinical data and 4D-derived assets could attract partners in a sector seeing renewed interest (Celltrion–KoBioLabs, Jul 2026). At KRW 49.5 bn market cap and about 1.2x book, little value is ascribed to the pipeline.

Bear case

  1. Listing-maintenance squeeze. Revenue of KRW 3.5–3.7 bn sits barely above today's KRW 3 bn floor and well below the KRW 5 bn (2027) and KRW 10 bn (2029) thresholds. Continued losses near half of equity (about KRW 42.5 bn derived) could trigger management-issue designation.

  2. Parent fatigue. CJ CheilJedang has put in about KRW 160 bn since 2021 with no technology-out and a terminated lead asset, while its own bio profits collapsed in 2026. Further support may come only on dilutive or restructuring terms (e.g., merger into an affiliate, privatisation or wind-down of drug R&D).

  3. Commoditised wellness market. Personalised gut testing and probiotics are crowded, low-barrier categories where several Korean microbiome firms are pursuing the same pivot. Scientific differentiation may not translate into pricing power, leaving the company with neither a drug franchise nor a scaled consumer business.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhy it matters
Commercial launch of personalised MAC solutionH2-2026 (by Dec 2026)First test of wellness revenue model
FY2026 business report (revenue vs KRW 3 bn floor; loss vs equity)~Mar 2027Listing-maintenance compliance; FY2027 KRW 5 bn threshold looming
Funding actions (new equity, parent loans, asset sales)Any timeDilution and parent-commitment signal
Pipeline updates on CJRB-201 / -302 / -401 and 4D assets; any partnering2026–2027Residual drug-development value
Peer-reviewed publication or full presentation of CJRB-101 Phase 1 data2026–2027Validation of the strain for wellness or future use
CJ CheilJedang portfolio decisions (bio division, CJ Wellcare integration)OngoingDetermines strategic home and funding of CJ Bioscience
Clinic partnership expansion and B2B testing volumesQuarterlyRevenue traction indicator
Headcount and R&D run-rate in Q3/Q4-2026 reportsNov 2026; Mar 2027Confirms cost reset

Analyst verdict

ChunLab entered public markets in 2019 as a credible scientific franchise. Its microbial reference data and taxonomy tools were widely used in academia, and it promised to turn that data advantage into diagnostics and drugs. CJ CheilJedang's 2021 acquisition, for about KRW 98 bn at KRW 37,465–40,000 per share, was a bet that group capital could accelerate the move from data to therapeutics.

Five years on, the outcome is clear in the numbers:

  • revenue has drifted down to KRW 3.7 bn;

  • annual operating losses of KRW 25–34 bn have produced an accumulated deficit of KRW 143 bn;

  • three rounds of equity issuance have been priced progressively lower;

  • the company's only clinical asset, CJRB-101, was withdrawn after Phase 1 in May 2026.

The share price, at KRW 3,720, is down more than 90% from the IPO and acquisition reference prices.

The current strategy is a rational retrenchment. Management is redeploying the company's genuine assets into precision nutrition and clinic-based testing, where CJ's consumer channels give it a route to market: Korean microbiome data, the Ez-Mx analytics platform, the DIGEST gut-simulation system and a growing human-study evidence base. Costs are falling quickly; H1-2026 operating losses were 13% lower year on year with a third fewer staff.

The constraint is time. KOSDAQ revenue thresholds rise to KRW 5 bn in 2027 and KRW 10 bn in 2029, and the parent is under its own earnings pressure.

Our assessment is that CJ Bioscience is now best analysed as a parent-dependent strategic option rather than a stand-alone investment case. Its equity value (about KRW 50 bn, roughly 1.2x book) mainly reflects residual platform and IP value plus the expectation of continued CJ support. The decisive monitorables are:

  • whether the H2-2026 MAC launch and clinic partnerships produce measurable revenue;

  • whether CJ CheilJedang continues to fund the company or restructures it.

Absent visible wellness traction by the FY2026 results, the risk of further dilution or corporate restructuring outweighs pipeline upside.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackground

Yoon Sang-bae (윤상배)

CEO (Representative Director)

Since 14 Aug 2025 (designated 8 Jul 2025)

Born 1970. BS and MS in Pharmacy, Chung-Ang University; MBA, KAIST. Career: Chong Kun Dang, Samsung C&T (bio business), GSK Korea, Dong-A ST, Boryung (~6 years, 2016–2021 period), then CEO of Huons (2022–2024). At Huons, consolidated revenue grew from KRW 492.4 bn (2022) to KRW 590.2 bn (2024). Received a presidential commendation on Mid-sized Enterprise Day (2024).

Chun Jongsik (천종식)

Adviser (R&D advisory, external networking); former founder-CEO

CEO Dec 2009 – Aug 2025

Founder; former Professor, School of Biological Sciences, Seoul National University (~20 years). Resigned professorship in Jan 2022 to run CJ Bioscience full-time. Led CJRB-101 into multinational Phase 1/2 and the 4D pharma asset acquisition.

Shin Chang-sik (신창식)

Head, Drug Research Group

—

Presented pipeline at IHMC 2026 industry session

Lee Je-hee (이제희)

Senior Manager, Wellness Research Group

—

Presented precision-nutrition platform at KMB 2026

“—” = not publicly disclosed.

Board & Management Changes

DateChangeContext

29 Dec 2021

CJ nominees appointed to board; Chun retained as CEO

Post-acquisition integration

8 Jul 2025

Yoon Sang-bae designated CEO

Company cited need for leadership to "leap a step" and execute drug-development strategy; also referenced premium health-functional-food ambitions

14 Aug 2025

Yoon formally appointed; Chun becomes adviser

Single-CEO structure

Major Shareholders

HolderStake (%)Date / basis

CJ CheilJedang Corp.

61.95

As reported Jul 2025 (after Aug-2023 rights at 120% take-up and Dec-2024 KRW 40 bn placement)

Chun Jongsik (founder)

6.65—

Free float (approximate, derived)

~30

100% less CJ stake and founder stake (if unchanged)

Competitive Landscape

Key Competitors

CompetitorCountryPositioning relative to CJ Bioscience

Seres Therapeutics

US

Developed SER-109 (VOWST), the first oral microbiome therapeutic, FDA-approved in Apr 2023. Commercial-stage precedent.

Ferring Pharmaceuticals (Rebyota)

Switzerland

First approved microbiome therapeutic (rectal); limited uptake reported

Vedanta Biosciences

US

—

MaaT Pharma

France

—

KoBioLabs (고바이오랩)

Korea

KGLP-007 in Phase 2 for ulcerative colitis (from 2021); licensed 3 candidates to Celltrion (Jul 2026); building health-functional-food revenue

Genome & Company (지놈앤컴퍼니)

Korea

Immuno-oncology microbiome programmes with Merck/MSD (Phase 2, 2023). Acquired US CDMO List Labs (60% for USD 27 m; ~KRW 10 bn annual revenue at acquisition). Cosmetics and supplements revenue (KRW 2.2 bn in 2023, 15.6% of revenue).

Enterobiome; Cell Biotech (쎌바이오텍)

Korea

Microbiome drug developers pivoting to functional-food and cosmetics revenue

Macrogen

Korea

Large NGS service provider; launched a microbiome business headquarters

Psomagen (Macrogen affiliate, KOSDAQ-listed)

US/Korea

NGS services; listed by Owler as a ChunLab competitor

GENEWIZ (Azenta)

US

Global sequencing services

QIAGEN (microbial genomics software); One Codex; CosmosID

Global

—

Peer Comparison FY2025

MetricCJ BioscienceKoBioLabsGenome & Company

Latest revenue

KRW 3.7 bn (FY2025)

——

Revenue growth

+6.5% (FY2025)

——

Operating margin

~-670% (FY2025, derived)

——

R&D intensity

663% of revenue (FY2024)

——

Most advanced asset

Preclinical (after CJRB-101 termination)

Phase 2 (UC)

Phase 2 (IO)

Market cap (Oct 2026)

~KRW 49.5 bn

——

Recent Developments

Sector context during the window: * In July 2026, Celltrion in-licensed three microbiome candidates from KoBioLabs. This is a signal of renewed large-pharma interest in Korean microbiome assets, but it does not involve CJ Bioscience.

Company Snapshot

$2.6M

Revenue

83

Employees

$36M

Market Cap

2009

Founded

Seoul, South Korea

Headquarters

SWOT Analysis

Strengths

  • Majority-parent financial backing. CJ CheilJedang owns 61.95% and has repeatedly funded the company: KRW 73.2 bn subscription (2021), 120% take-up of the 2023 rights issue, KRW 33.1 bn building purchase (2023) and KRW 40 bn placement (2024).
  • Scientific reputation in microbial taxonomy. The EzBioCloud reference database was cited 8,500+ times by 2019, and the Precision Taxonomy Platform had catalogued 5,924+ novel taxa.
  • Proprietary Korean microbiome datasets. These include a life-cycle gut map (Jan 2026), a 543-person diet-score dataset and a 186-person dietary intervention study (2026).
  • Integrated precision-nutrition platform. Ez-Mx, DIGEST/DIGEST-Flow (patent pending) and an ML response-prediction model with ROC-AUC 0.85 (Jun 2026).
  • Acquired discovery platforms and IP. MicroRx and MicroDx plus 4D pharma's patent library and 9 candidates (Mar 2023).
  • Demonstrated clinical execution. FDA IND cleared in Jan 2023 and MFDS IND in Jun 2023; the Phase 1 trial ran across 4 sites in 2 countries; first-in-human safety data were presented at ASCO 2025.

Weaknesses

  • Subscale revenue. KRW 3.7 bn in FY2025, below the FY2020 level of KRW 5.3 bn, with a FY2021–FY2025 CAGR of about -4.2%.
  • Structural losses. Operating losses of KRW 24.8–34.2 bn a year in FY2022–FY2025; accumulated deficit of KRW 143.3 bn at end-2025.
  • Negative operating cash flow. KRW -23.4 bn in FY2025, with rising short-term borrowings reported in 2025.
  • No clinical-stage asset remaining. CJRB-101 was terminated in May 2026; CJRB-201, -302 and -401 are early-stage.
  • Missed strategic targets. Two technology-outs by 2025 (2022 target) and three by 2026 (2024 target) were both not achieved.

Opportunities

  • Commercial launch of the personalised MAC solution (planned H2-2026), building on the IHMC 2026 and KMB 2026 data.
  • Group distribution synergies with CJ Wellcare. Its BYOCORE brand and Amazon, Shopee and Tmall channels could carry microbiome-tailored products.
  • GLP-1 side-effect management and metabolic-disease applications, explicitly targeted for the precision-nutrition platform (Jun 2026).
  • Clinic partnerships (Mediram, Sun Medical Center, BeautyOn Clinic) that can scale B2B testing revenue.
  • Out-licensing of preclinical assets (CJRB-201 IBD data from Jun 2026; 4D-derived assets) amid renewed big-pharma interest, as shown by Celltrion–KoBioLabs (Jul 2026).
  • Tighter group integration. CJ CheilJedang's restructuring (Jul 2026) and earlier signals (Nov 2024) that red bio might gain group focus could bring more support.

Threats

  • KOSDAQ delisting/management-issue criteria. The revenue floor rises to KRW 5 bn (2027) and KRW 10 bn (2029), versus FY2025 revenue of KRW 3.7 bn. The pre-tax-loss-to-equity test may also bite given FY2025 losses of about KRW 24 bn against equity of about KRW 42.5 bn (derived).
  • Parent capacity and appetite. CJ CheilJedang's Q1-2026 bio operating profit fell 92.4% YoY, and media describe the subsidiary as a burden ("계륵").
  • Therapeutic-class risk. More than 100 microbiome drugs are in development against about 2 FDA approvals, and approved products have struggled commercially.
  • Intense competition in consumer gut testing and probiotics, as many Korean microbiome developers pivot to supplements and cosmetics.
  • Dilution risk. Funding has relied on equity issuance in 2021, 2023 and 2024, at progressively lower prices (KRW 37,465, then 14,110, then 10,119).
  • Regulatory and claims risk for personalised nutrition and testing products (health-functional-food and medical-claims boundaries in Korea). This is an analyst assessment; no specific action has been identified.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Mar 2025CJRB-101 Phase 1 enrolment completed (reported Feb 2026)Data readout pathway opened
2 Apr 2025Press analysis highlights KOSDAQ listing-maintenance risks (pre-tax loss/equity test; KRW 3 bn revenue floor) and two consecutive years of equity raisesMarket framing shifts to sustainability
15 May 2025Q1-2025 quarterly report filedRoutine
30 May 2025ASCO 2025 poster: CJRB-101 plus pembrolizumab in 32 solid-tumour patients; no DLT; one grade 3 or higher TRAE (anaemia); some tumour shrinkageFirst human data; safety supportive, efficacy signal limited
8 Jul 2025Yoon Sang-bae (ex-Huons CEO) designated CEO; founder Chun to become adviserShift toward commercial and operational leadership
14 Aug 2025Yoon formally appointed CEO; H1-2025 report filed (revenue ~KRW 1.7 bn; R&D KRW 9.2 bn; operating loss KRW 13.55 bn)Leadership change effective
26 Sep 2025Industry coverage notes three ex-Boryung executives now leading Hugel, CJ Bioscience and Theragen EtexContext on CEO network
30 Sep 2025Analysis reports rising short-term borrowings and most pipelines still early-stageBalance-sheet pressure
14 Nov 2025Q3-2025 quarterly report filedRoutine
22 Dec 2025Shares reach 52-week high of KRW 10,200Peak before 2026 de-rating
15 Jan 2026Gut-microbiome analysis service introduced at Mediram Korean Medicine HospitalWellness / clinical revenue channel
19 Jan 2026Korean gut microbiome life-cycle map publishedData asset for personalised products
30 Jan 2026MOU with Sun Medical Center on gut-microbiome-test-based healthcareClinical channel
2 Feb 2026Expanded scientific evidence for personalised dietary solutions announcedPrecision-nutrition groundwork
20 Feb 2026Press questions feasibility of the "3 tech-outs by 2026" target; Phase 2 timing slippedExpectations reset
16 Mar 2026FY2025 business report filed: revenue KRW 3.7 bn (+6.5%); operating loss KRW 24.8 bn; net loss KRW 24.0 bn; operating cash flow KRW -23.4 bn; accumulated deficit KRW 143.3 bnLosses narrowing; revenue remains subscale
25 Mar 2026MOU with BeautyOn Clinic Dolgoji on skin–gut correlation researchBeauty/wellness adjacency
31 Mar – 3 Apr 2026Dealsite questions whether the subsidiary has become a burden to its parent ("계륵")Parent-support uncertainty
12 May 2026CJRB-101 Phase 1/2 (US and Korea) terminated early; IND voluntarily withdrawn; no Phase 2Loss of lead clinical asset; strategic pivot to wellness
15 May 2026Q1-2026 report: revenue KRW 0.78 bn (-14.2%); operating loss KRW 5.3 bn; R&D KRW 3.3 bnRevenue weakness persists
25–26 May 2026Press reports CJ CheilJedang has committed ~KRW 160 bn since 2021; notes parent's Q1-2026 operating profit down 26%Parent capacity question
1–5 Jun 2026IHMC 2026 (Seoul): 3 posters and 2 sessions; announces H2-2026 launch of personalised MAC solutionCommercial wellness roadmap
24–26 Jun 2026KMB 2026: precision-nutrition integrated platform (Ez-Mx, DIGEST, 186-person study, ML prediction); CJRB-201 preclinical dataPlatform positioning; IBD pipeline evidence
1 Jul 2026Parent CJ CheilJedang reorganises into three divisions (Lifestyle Food, Technology Materials, Core Materials)Parent strategic context
30 Jul 2026Shares hit 52-week low of KRW 3,060Post-termination trough
14 Aug 2026H1-2026 report: revenue KRW 1.68 bn (flat YoY); operating loss KRW 11.74 bn (vs 13.55 bn); headcount 83 (vs 124)Cost discipline evident
28 Aug 2026Large business group status disclosure (quarterly, individual company)Routine group compliance
19 Oct 2026Shares close at KRW 3,720; market cap ~KRW 49.5 bn; P/B 1.19xCurrent valuation reference

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment: Total company revenue fell from KRW 5,600 Mn in FY2023 to KRW 3,700 Mn in FY2025.
ChunLab, Inc. — Revenue by Segment
Series (KRW Mn)FY2023FY2024FY2025
Total company revenue5,6003,5003,700

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. MarketScreener: CJ CheilJedang acquisition of 15.99% stake in ChunLab (2021). (marketscreener.com)
  2. BioSpectator: ChunLab KOSDAQ preliminary review filing (2019). (biospectator.com)
  3. BioSpectator: ChunLab preliminary approval (2019). (biospectator.com)
  4. BioSpectator: ChunLab precision taxonomy discovery platform / CLCC1 (2020). (biospectator.com)
  5. Korea JoongAng Daily: ChunLab personalised gut healthcare service. (koreajoongangdaily.com)
  6. Dealsite: ChunLab renamed CJ Bioscience (Dec 2021). (dealsite.co.kr)
  7. Dealsite: microbiome IPO pipeline / ChunLab valuation and Australian subsidiary (2020). (dealsite.co.kr)
  8. Korea IR Council / Korea Data technology analysis report on ChunLab (Apr 2020). (ssl.pstatic.net)
  9. Korea JoongAng Daily: CJ CheilJedang launches microbiome subsidiary. (koreajoongangdaily.com)
  10. Korea Times: CJ CheilJedang to launch bioscience brand (Dec 2021). (koreatimes.co.kr)
  11. BioSpectator / Kormedi / Medigate / Financial News: CJ Bioscience launch (Jan 2022). · kormedi.com · medigatenews.com · fnnews.com
  12. Dailypharm (EN): CJRB-101 IND submission (Dec 2022). (dailypharm.com)
  13. BioSpectator: CJRB-101 FDA IND approval (Jan 2023). (biospectator.com)
  14. ClinicalTrials.gov NCT05877430. (clinicaltrials.gov)
  15. Larvol VERI: CJRB-101 trial record. (veri.larvol.com)
  16. Patsnap Synapse: CJRB-101 (ASCO 2025 result). (synapse.patsnap.com)
  17. Medigate News: FY2022 preliminary results (Feb 2023). (medigatenews.com)
  18. Dealsite: FY2022 losses widen. (dealsite.co.kr)
  19. KED Global: 4D pharma asset acquisition (Mar 2023). (amp.kedglobal.com)
  20. BioSpectator: 4D pharma deal detail.: biospectator.com:443
  21. TheBusinessDesk: 4D pharma administration sale. (thebusinessdesk.com)
  22. KED Global: 2023 rights offering. (kedglobal.com)
  23. BioSpectator: 2023 rights offering. (biospectator.com)
  24. Medigate News / CJ Newsroom: rights subscription 108.33% (Aug 2023). · cjnews.cj.net
  25. Tax Finance Media: CJ CheilJedang participation in rights issue. (tfmedia.co.kr)
  26. BioSpectator: 15-programme pipeline (Jul 2023). (biospectator.com)
  27. Dealsite: HQ building sale to CJ CheilJedang (Dec 2023). (dealsite.co.kr)
  28. CJ Newsroom: 2024 New Vision. (cjnews.cj.net)
  29. Dailypharm: CJ Bioscience 3 years / tech-out targets (Jun 2024). (dailypharm.com)
  30. Dailypharm: CJ bio restructuring and stock surge (Nov 2024). (m.dailypharm.com)
  31. Asia Economy: limit-up on bio sale report (Nov 2024). (core.asiae.co.kr)
  32. Aju News / Asia Economy / BioSpectator: KRW 40 bn placement (Dec 2024). · core.asiae.co.kr · biospectator.com
  33. IB Tomato: sustainability and listing-maintenance risks (Apr 2025). (newstomato.com)
  34. Medigate News / Sidae / Dailypharm: CEO change (Jul–Sep 2025). · sidae.com · dailypharm.com · dailypharm.com
  35. CEO Score Daily: R&D trend and borrowings (Sep 2025). (ceoscoredaily.com)
  36. Newspim: tech-out target deadline (Feb 2026). (newspim.com)
  37. Dealsite: "인수 5년차 CJ바이오사이언스, '계륵' 됐나" (Apr 2026). (dealsite.co.kr)
  38. Newspim / CBC News: CJRB-101 termination (May 2026). · cbci.co.kr
  39. Asia Today: ~KRW 160 bn invested; Q1-2026 (May 2026). (asiatoday.co.kr)
  40. CJ Newsroom tag pages (2026 press releases). (cjnews.cj.net)
  41. Money Today / Dailypharm / Asia Economy: IHMC 2026 and MAC solution (Jun 2026). · dailypharm.com · view.asiae.co.kr
  42. Dailypharm / Financial News / Metro: precision-nutrition platform at KMB 2026. · fnnews.com · metroseoul.co.kr
  43. Medipana: H1-2026 AI drug developers results. (medipana.com)
  44. Seoul Times News: CJ affiliates headcount and H1-2026. (seoultimes.news)
  45. Butler.works: 5-year financial summary and segment mix. (butler.works)
  46. ChickStock: price, valuation, FY2025 data (19 Oct 2026). (chickstockfi.com)
  47. Judal: market data snapshots (Sep 2026). (judal.co.kr)
  48. IRGO: CJ Bioscience filing index. (m.irgo.co.kr)
  49. THE VC: company registry snapshot. (thevc.kr)
  50. Jasoseol: company profile (address, employees). (jasoseol.com)
  51. Jasoseol: CJ Wellcare profile. (jasoseol.com)
  52. Saramin: company profile (CEO, address). (saramin.co.kr)
  53. Owler: ChunLab profile and competitor list. (owler.com)
  54. BioSpectator: Genome & Company acquisition of List Labs. (biospectator.com)
  55. Kukinews: Korean microbiome companies pivot to supplements/cosmetics (2024). (kukinews.com)
  56. Kormedi: Celltrion in-licenses KoBioLabs candidates (Jul 2026). (kormedi.com)
  57. Newsway / Newscj / Nate (Newsis): CJ CheilJedang and CJ bio performance 2026. · newscj.com
  58. Financial News: microbiome market context (Oct 2021). (fnnews.com)
  59. Dealsite: Genome & Company / Seres approval context (2023). (dealsite.co.kr)

Primary and secondary sources consulted (accessed Oct 2026):

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.